1. Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab
- Author
-
Didier Hannequin, Jared R. Brosch, B. Joy Snider, Anna Santacruz, Anne M. Fagan, Suman Jayadev, William S. Brooks, Colin L. Masters, Erik D. Roberson, Mario Masellis, Susan Mills, Christopher H. Dyck, Florence Pasquier, Paulo Fontoura, Bruno Dubois, Monika Baudler, Lawrence S. Honig, Doug R. Galasko, James J. Lah, Peter J. Snyder, David Wallon, Geoffrey A. Kerchner, Eric McDade, Guoqiao Wang, Andrew J. Aschenbrenner, Jason Hassenstab, Roy Yaari, Ghulam M. Surti, Raquel Sánchez-Valle, Jérémie Pariente, Stephen Salloway, Carlos Cruchaga, Randall J. Bateman, Ivonne Z. Jimenez-Velazquez, Robert A. Koeppe, John C. Morris, Serge Gauthier, Clifford R. Jack, Sarah B. Berman, Alison Goate, Catherine J. Mummery, Martin R. Farlow, Karen C. Holdridge, Rachelle S. Doody, Tammie L.S. Benzinger, Scott W. Andersen, Chengjie Xiong, Ging-Yuek Robin Hsiung, Roger Clarnette, Paul Delmar, Maïté Formaglio, Mark A. Mintun, Kelley Coalier, John R. Sims, Brian A. Gordon, and David B. Clifford
- Subjects
Physics ,Epidemiology ,Health Policy ,Geometry ,Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,Developmental Neuroscience ,medicine ,Neurology (clinical) ,Solanezumab ,Geriatrics and Gerontology ,Line (text file) ,Gantenerumab ,medicine.drug - Published
- 2020
- Full Text
- View/download PDF